Chemoradiation with 5-fluorouracil and mitomycin remains the standard of care for squamous cell carcinoma (SCC) of the anal canal. A prolonged treatment time is associated with inferior disease-specific outcomes. Radiation Therapy Oncology Group trial 0529 demonstrated decreased toxicity and fewer treatment breaks with intensity-modulated radiotherapy (IMRT), but this has not been assessed in a randomized trial. Using data from the National Cancer Data Base (NCDB), this study evaluated the impact of IMRT on treatment time and survival in anal SCC. METHODS: The NCDB was used to identify patients with anal cancer from 2004 to 2013. The included patients were those with stage I to III squamous cell cancer of the anal canal who had received definitive chemoradiation by IMRT or 3-dimensional conformal radiation therapy (3DCRT). Statistical analyses were performed with logistic regression, Kaplan-Meier analysis, Cox proportional hazards analysis, and propensity score-matched analysis. RESULTS: Of 6814 patients, 57.4% were treated with 3DCRT, whereas 42.6% received IMRT. Patients receiving IMRT had a reduced risk of a long treatment time in a multivariate analysis (P < .001). The 5-year overall survival (OS) rates with IMRT and 3DCRT were 80.8% and 78.9%, respectively (P = .0036). According to a propensity analysis, patients receiving IMRT had improved OS (P = .039) and a reduced risk of a long treatment time (P < .0001) in a multivariate analysis. CONCLUSIONS: IMRT use was associated with significantly reduced overall treatment time and improved survival in comparison with 3DCRT. It is important to note that NCDB data are not as robust as randomized data. However, these results further support the use of IMRT as part of sphincter-preserving therapy for the anal canal.
INTRODUCTION
The standard of care for the treatment of squamous cell carcinoma (SCC) of the anal canal remains radiation with concurrent 5-fluorouracil (5-FU) and mitomycin (MMC)-based chemotherapy. Disease-free survival is quite good with this approach; however, chemoradiation is often associated with significant toxicity. This can result in treatment breaks and prolongation of total treatment times, which adversely affect cancer outcomes. [1] [2] [3] Radiation Therapy Oncology Group (RTOG) trial 9811 investigated the use of induction chemotherapy followed by 5-FU with cisplatin chemoradiation versus chemoradiation with 5-FU and MMC. 1 The induction arm had a worse colostomy-free rate, worse disease-free survival, and worse overall survival (OS) at 5 years, potentially because of prolongation of the overall treatment time. 1 An increase in the overall treatment time has also been associated with higher colostomy rates in secondary analyses of other RTOG anal cancer trials. 2, 3 The real difficulty in administering standard chemoradiation with 5-FU and MMC is the significantly high rates of grade 3 or higher acute morbidities. Intensity-modulated radiotherapy (IMRT) is a form of advanced radiation delivery that uses fluctuating radiation-beam intensities to target the radiation dose to the tumor while minimizing the dose to the surrounding normal organs. Several studies, including the phase 2 RTOG 0529 trial, have demonstrated that the improved conformality with IMRT, in comparison with traditional 3-dimensional (3D) conformal techniques (3-dimensional conformal radiation therapy [3DCRT]), results in toxicity reduction in comparison with historical controls 4, 5 with favorable efficacy rates. 6, 7 However, IMRT has not been compared with 3DCRT in a randomized fashion, although it has been widely embraced for the treatment of anal cancer on the basis of the totality of the prospective data.
Because of the relatively low incidence of anal cancer, existing funding resources, and compelling phase 2 data supporting the use of IMRT, a randomized trial directly comparing IMRT and 3DCRT in this population is unlikely to
Cancer November 15, 2018 occur. Therefore, using the National Cancer Data Base (NCDB), we performed a large database analysis with the hypothesis that treatments administered with IMRT have significantly reduced treatment times and improved survival in comparison with 3DCRT.
MATERIALS AND METHODS

Data Source
The NCDB is a national oncology outcome database that includes more than 1500 Commission on Canceraccredited programs. Data have been collected since 1989, and there are now approximately 34 million records from hospital cancer registries nationwide. The data provided by the NCDB were imported into SAS 9.3 (SAS Institute, Cary, North Carolina) with the provided coding along with the Participant User File (PUF). The study was exempt from Institutional Review Board approval since existing, de-identified, retrospective data from the NCDB was used. The NCDB provides data without charge to the general public, researchers, and clinicians.
Study Population
The NCDB was used to identify patients with anal cancer from 2004 to 2013 from the PUF. Records of those older than 18 years were included. SCC was identified with histology codes 8053 to 8079, and other values were excluded. The total radiation dose included the target volume plus any boost and ranged from 3600 to 5940 cGy, the number of treatment fractions ranged from 25 to 40, and the treatment time ranged from 25 to 180 days. Treatment volumes were included for the pelvis, nodes, and soft tissue only. All other sites for treatment were excluded. Patients outside these criteria were removed from the analysis. Any treatments outside the reporting facility were excluded. Only American Joint Committee on Cancer analytic stage groups I to III were included. In addition, any reports of surgery, not receiving chemotherapy, receiving any palliative therapy, or not receiving any radiation were excluded from the analysis. Only the modalities coded as 3D conformal or IMRT were included in the analysis. From a total eligible population of 48,345 patients, there were 6814 available for analysis after all of the inclusion/exclusion criteria had been met.
Study Variables
Patient-specific characteristics included age, sex, and race. Elderly was defined as an age ≥ 65 years. Race was broken into white, black, and other. Patient disease characteristics included grade, size, and stage. A tumor grade of 3 to 4 was defined as high. The Charlson-Deyo Comorbidity Index was used as a tool for assessing comorbidities and was coded as a 0, 1, or 2 to demonstrate an increasing level of comorbidity. Income was estimated in the NCDB by zip code and was broken into quartiles. We defined a lowincome region as one with a median household income of less than $38,000 in the patient's area of residence by zip code according to 2012 American Community Survey data. A middle-income region was defined as one with a median household income of $38,000 to $62,999, and a high-income region was defined as one with a median household income of $63,000 or greater. 
Outcomes
OS was used as the primary outcome and was defined as the time from the date of first treatment to death or last follow-up. A long treatment time was identified as an additional outcome of interest. Dichotomously, a long treatment time was defined as longer than the upper quartile for treatment days (54 days). A short treatment time was less than 42 days, and a midtreatment time was 42 to 53 days.
Statistical Analysis
The statistical analysis was conducted with SAS 9.3 (SAS Institute, Cary, North Carolina). The SAS import code and label file provided with the PUF were used. The frequency and distribution of patient demographic and disease characteristics were assessed. The significance level was set at P < .05. t tests, an analysis of variance, and Cochran-Mantel-Haenszel P values were generated for basic associations. A univariate analysis was conducted with the Cox proportional hazards for the overall risk
Cancer November 15, 2018 of death (OS), with hazard ratios (HRs) and 95% confidence limits reported. Values found to be of significance were then included in a multivariate analysis to control for potential confounders. Logistic regression analysis was used with a long treatment time defined as a dichotomous variable to determine associations influencing the risk of a long treatment time. These results were reported as odds ratios (ORs) and 95% confidence interval (CIs). Kaplan-Meier plots were generated to compare the survival curves by significant variable subgroups and were presented with log-rank P values. Individuals with variables with missing values were excluded from the analysis.
Because of the potential selection bias involved in using IMRT, a propensity score matching analysis was performed. The algorithm for SAS provided by Lori Parsons of the Ovation Research Group was used. 8 Propensity scores were generated with a logistic regression model with IMRT utilization as the dependent variable and with age, sex, race, Charlson-Deyo Comorbidity Score, primary payer, year of diagnosis, income, education, facility type, and facility location as the independent Cancer November 15, 2018 variables. Each of these variables could have potentially influenced whether a patient received IMRT or not and could have introduced a selection bias. The 3DCRT and IMRT groups were then matched on those variables to balance the cohort. Patients were matched 1:1 with best matches and next best matches according to an 8-digit propensity score. The algorithm attempted to match patients first on all 8 digits, then on 7 digits, and so forth until the lowest digit matched. Incomplete matching resulted from missing data, a disjointed range of propensity scores, and a failure to match on the specified number of digits. 8 If any data were missing, the patient was removed from the analysis, and a propensity score was not calculated. After the algorithm was run, a total of 4378 patients (2189 per group) remained for a propensity score-matched analysis. Univariate and multivariate Cox proportional hazards analyses were run again with the same variables before propensity matching.
RESULTS
There were a total of 6814 patients who met the inclusion criteria ( Fig. 1) : 3912 (57.4%) were treated with 3DCRT, whereas 2902 (42.6%) received IMRT. Approximately equal percentages of IMRT and 3DCRT recipients had similar demographic characteristics. The average length of treatment for all patients was 48.9 days (range, 25-176 days). The mean treatment durations for IMRT patients and 3DCRT patients were 47.7 and 49.9 days, respectively (P < .001); 965 patients (33.3%) received IMRT treatment at a high-volume center, whereas 942 (24.1%) received 3DCRT at a high-volume center (Table 1) .
Among the patients treated with 3DCRT, 29.6% (n = 1159) had a long treatment time, whereas 20.2% (n = 586) of those treated with IMRT did (P < .0001). Those treated with IMRT had a reduced risk of having a long treatment (OR, 0.60; 95% CI, 0.54-0.67; P < .001). After we controlled for sex, race, comorbidity score, stage, income, and center volume, patients receiving IMRT still had a reduced risk of a longer treatment time in a multiple logistic regression analysis (OR, 0.62; 95% CI, 0.55-0.69; P < .001).
Kaplan-Meier plots demonstrated improved OS for those treated at a high-volume center (P = .0011) and for those with a shorter treatment time (P < .0001; Fig. 2 ). High-, intermediate-, and low-volume facilities had 5-year OS rates of 75.3%, 70.7%, and 69.1%, respectively. The 5-year OS rates with short, mid, and long treatment times were 77.1%, 72.6%, and 64.8%, respectively. IMRT patients had improved OS in comparison with 3DCRT patients (P = .0036; Fig. 3A) . The 3-, 5-, and 10-year OS rates with IMRT and 3DCRT were 85.0% and 80.2%, 81.2% and 75.0%, and 80.2% and 70.3%, respectively.
The univariate analysis for the hazard of death comparing IMRT and 3DCRT with Cox proportional hazards is displayed in Table 2 . Furthermore, this table includes the univariate analysis of the other variables examined for the hazard of death. IMRT demonstrated a reduced hazard of death in comparison with 3DCRT (HR, 0.85; 95% CI, 0.75-0.95; P = .0037). In addition, being treated at a high-volume center (HR, 0.80; 95% CI, 0.70-0.91; P = .0008) and being white (HR, 0.81; 95% CI, 0.70-0.95; P = .007) were associated with a decreased hazard of death. A long treatment time was associated with an increased hazard of death (HR, 1.47; 95% CI, 1.32-1.64; P < .0001).
The results of a Cox proportional hazards multivariate analysis comparing IMRT and 3DCRT and controlling for potential confounders are shown in Table 3 . IMRT demonstrated a 15% decrease in the hazard of death in comparison with 3DCRT after we controlled for age, sex, comorbidity score, treatment time, race, income, stage, and center volume (HR, 0.85; 95% CI, 0.76-0.95; P = .0049).
Because of the nonuniform use of IMRT across the population, which was influenced by multiple potentially measurable factors, a propensity score-matched analysis was also conducted. Table 6 presents these variables and the frequency of each within the IMRT and 3DCRT groups; it demonstrates an overall good balance. With this matched pairs analysis, IMRT patients still had improved OS in comparison with 3DCRT patients with univariate Cox proportional hazards (HR, 0.84; 95% CI, 0.73-0.97; P = .018; Table 4 ). After we controlled for age, sex, comorbidity score, treatment time, income, stage, Cancer November 15, 2018 and center volume in the multivariate analysis, IMRT retained a survival benefit (HR, 0.86; 95% CI, 0.74-0.99; P = .039; Table 5 ). In addition to OS, IMRT patients continued to have a reduced risk of a long treatment time in the propensity score-matched multivariate analysis after we controlled for sex, comorbidity score, stage, income, and center volume (HR, 0.71; 95% CI, 0.62-0.82; P < .0001). The propensity-matched Kaplan-Meier plot demonstrated improved OS for IMRT (P = .0172; Fig. 3B ). The propensity-matched 3-, 5-, and 10-year OS rates for IMRT and 3DCRT were 85.3% and 82.7%, 80.8% and 78.9%, and 79.7% and 76.7%, respectively. Cancer November 15, 2018 
DISCUSSION
In this large database analysis, we stratified patients with SCC of the anal canal into those who received IMRT for definitive chemoradiotherapy and those who received 3DCRT. Our findings demonstrate that IMRT-treated patients have a lower risk of a prolonged treatment time with significant improvements in OS in comparison with 3DCRT-treated patients. There was a significant 2.6% reduction in the risk of death at 3 years, there was a 1.9% reduction in the risk of death at 5 years, and there was a 3% reduction in the risk of death at 10 years. It is well known that prolongation of the overall treatment time adversely affects the survival of patients undergoing chemoradiation for SCC of the anal canal.
1-3 A nonrandomized phase 2 trial from the Eastern Cooperative Oncology Group (4292) assessed high-dose radiotherapy to 59.4 Gy with concurrent 5-FU and cisplatin. 9 The first cohort of 19 patients received 36 Gy, and this was followed by a planned 2-week treatment break before the completion of the remainder of the treatment. A second cohort of 13 patients received the total dosage of 59.4 Gy and chemotherapy without a planned break. The planned radiation gap proved to be deleterious, with superior outcomes observed in patients not receiving a break: the complete response rates were 92% and 68%, the 5-year progression-free survival rates were 85% and 53%, and the 5-year OS rates were 84% and 58%. To further assess whether the overall treatment time adversely affected outcomes, investigators from RTOG performed an analysis based on completed anal cancer trials and observed a significant association between overall treatment duration and colostomy failure, local failure, regional failure, and time-to-failure rates. 2 In light of the totality of these results and the superior outcomes for patients from the RTOG 9811 and Anal Cancer Trial (ACT) II trials who were not treated with a planned treatment gap, a prolonged total chemoradiation duration significantly correlates with inferior outcomes. 10, 11 Cancer November 15, 2018 One practical advantage is that the use of IMRT in anal cancer may reduce the chemoradiation acute side effect profile and prevent or reduce the treatment breaks that negatively affect outcomes. IMRT is known to improve the conformality of the radiation dose, which can reduce the dose to pelvic organs at risk. Early dosimetric studies and retrospective experiences have suggested reduced doses to the small bowel, genitalia, and bladder with IMRT versus 3DCRT. 5, 6 RTOG 0529 was a phase 2, prospective trial assessing the use of IMRT for anal cancer in a multicenter setting. Acute toxicity was compared with that for patients treated with 3DCRT in the standard MMC arm of RTOG 9811. For IMRT patients, there were significantly fewer combined grade 3 or higher gastrointestinal toxicities (21% vs 36%; P = .0052), grade 2 or higher hematologic toxicities (73% vs 85%; P = .032), and grade 3 or higher dermatologic toxicities (23% vs 49%; P = .0052). In addition, other smaller series have demonstrated a reduction in grade 3 or higher gastrointestinal, hematologic, and dermatologic toxicities without a reduction of locoregional control. [12] [13] [14] [15] The reduction of grade 3 or higher events may be one reason for the survival benefit demonstrated in our analysis.
In the RTOG 0529 trial, treatment breaks due to toxicity were needed by 49% of those receiving IMRT and by 62% of those conventionally treated. 7 In our study, IMRT had a mean length of treatment of 47.7 days, whereas 3DCRT had a mean length of treatment of 49.9 days. These times are comparable to those demonstrated in RTOG 0529 (median treatment time with IMRT, 42.5 days) and RTOG 9811 (49 days). However, in our study, we were able to demonstrate that 3DCRT increased the risk of a patient having more treatment days than the upper quartile (>54 days). In previous retrospective studies, treatment with IMRT has been shown to significantly reduce the number of patients requiring a treatment break. 6, [16] [17] [18] Kachnic et al 17 demonstrated that 40% of patients receiving IMRT needed a treatment break; this was similar to what was seen by Salama et al 6 (42%). Each of these studies also demonstrated a significantly reduced need for treatment breaks for those receiving IMRT. 6, 10, 17 Similarly to our data, Chuong et al 18 demonstrated an OS benefit from IMRT versus 3DCRT in a small institutional series with 3-year OS rates of 91.1% and 86.1%, respectively. This study included 89 consecutive patients, with 52 receiving IMRT and 37 receiving 3DCRT; the median follow-up was 26.5 months for all patients. Furthermore, it was demonstrated that more patients in the 3DCRT group needed a treatment break (11 vs 4; P = .006). Cancer November 15, 2018 Our study has demonstrated that high-volume facilities have better survival outcomes than those facilities that treat anal cancer less frequently. Recently, Amini et al 19 used the NCDB to show that high-, intermediate-, and low-volume academic facilities had 5-year OS rates of 76.1%, 73.4%, and 69.2%, respectively. In addition, this study reported that high-, intermediate-, and low-volume nonacademic facilities had 5-year OS rates of 74.6%, 71.4%, and 70.1%, respectively. Our findings were similar: high-, intermediate-, and low-volume facilities (for all facility types) had 5-year OS rates of 75.3%, 70.7%, and 69.1%, respectively. This difference may be due to higher volume facilities having more experience in managing acute toxicities. This demonstrates that the facility type may be as influential as IMRT for the hazard of death. However, IMRT remained significant in a multivariate analysis after we controlled for this potential confounder.
The reduction of grade 3 or higher events and the decreased treatment time may have contributed to the survival benefit demonstrated in our analysis. The NCDB records the number of days that a patient is under treatment from the start of therapy to the completion of therapy. In our study, we were able to demonstrate that patients receiving 3DCRT had a significantly longer treatment time than those patients receiving IMRT. IMRT was associated with a mean length of treatment of 47.7 days, whereas 3DCRT was associated with a mean of 49.9 days. These are comparable to the times demonstrated in RTOG 0529 (median treatment time with IMRT, 42.5 days) and in the MMC arm of RTOG 9811 (49 days). 7 However, it is worth noting that RTOG 0529 did not meet its pre-established toxicity endpoints. In this analysis, we were also able to demonstrate that 3DCRT increased the risk of a patient having more treatment days than the upper quartile (>54 days). It is assumed that the long treatment time is due to treatment breaks from acute toxicity; however, one important limitation of this analysis is that the NCDB does not record radiation or chemotherapy toxicity data. In addition to the reduction in toxicities, IMRT may allow improved regional target coverage, which could be a factor contributing to improved survival.
Another major limitation of our study is the nonuniform delivery of IMRT. From 2004 to 2013 (our data time frame), the use of IMRT increased, and this presents a large selection bias. 20 In addition, factors such as the region, facility type (ie, academic or private), and insurance status may also have affected whether or not a patient received IMRT. Our propensity score-matched analysis was able to mitigate many of these confounders but then limited our sample population from 6814 to 4378. In addition to the changes in the use of IMRT over time, there was also stage migration over time. The propensity-matched analyses may have helped to control this limitation as well. However, despite the ability to control for known potential confounders, propensity matching is unable to control for unknown confounders, which may influence the results.
This analysis has several other limitations worthy of mention. The NCDB is primarily a surgical database, and analyses are limited by the variables that are recorded. Similarly to other large database studies and registries, coding biases due to different coders across multiple hospital systems may exist. This allows more human error in data collection and leads to unmeasurable confounding factors. Lastly, although we have accounted for treatment at high-volume centers in the analyses, unaccounted differences in supportive care and experiences in managing acute toxicity can exist, and this may influence the total treatment time.
Because IMRT has demonstrated efficacy similar to that of 3DCRT 6, 7 and has been shown to decrease acute toxicity, IMRT-based chemoradiation therapy is now the standard of care for the treatment of SCC of the anal canal. 21 As such, and because a future randomized trial comparing IMRT and 3DCRT is unlikely, this study offers further evidence supporting the use of IMRT.
In conclusion, according to this large NCDB analysis, patients with anal cancer treated with IMRT appear to have a reduced risk of a prolonged treatment time and improved survival in comparison with patients receiving conventional radiation therapy. These findings lend further support to the continued use of IMRT, which is the current standard of practice, for the treatment of anal cancer in the absence of randomized trial data.
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